Status:

COMPLETED

Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain

Lead Sponsor:

Allevio Pain Management Clinic

Conditions:

Chronic Neuropathic Pain and Fibromyalgia

Eligibility:

All Genders

18-90 years

Phase:

PHASE4

Brief Summary

As lidocaine and ketamine provide analgesia by acting on different molecular pathways, administering them together may produce synergistic effects, which can allow for using a lower dose of each medic...

Detailed Description

Study objectives 1. To evaluate effectiveness of lidocaine-ketamine infusions in reducing neuropathic pain, as assessed using the Revised Pain Quality Assessment Scale (PQAS-R) and Short Form Brief P...

Eligibility Criteria

Inclusion

  • Pain duration \> 3 months;
  • Multifocal and/or non-dermatomal neuropathic pain per Pain Diagram;
  • Failed medical management with at least 2 neuromodulation agents (e.g., gabapentinoids, antidepressants, cannabinoids);
  • Neuropathic component (12 or more points on S-LANSS);

Exclusion

  • Non-English speakers;
  • Refusal to sign informed consent;
  • Allergy to ketamine and/or lidocaine;
  • Known relative contraindications to ketamine use which include poorly controlled systemic illnesses: hypertension, hyperthyroidism, ischemic heart disease, heart failure, psychiatric comorbidity (e.g., psychosis, schizophrenia, dissociative state);
  • Known contraindication to lidocaine use which include current symptomatic or clinically significant brady- or tachyarrhythmia, systolic blood pressure \<90 or \>180 mmHg;
  • Scheduled interventions targeting neuropathic pain: epidural injections, peripheral nerve blocks, Bier block, radiofrequency of dorsal root ganglia and peripheral nerves, additional lidocaine or ketamine infusions;
  • Newly added analgesic or neuromodulating medications within 30 days;
  • Recently performed neuromodulating interventions within 90 days;
  • Previous lidocaine-ketamine, lidocaine or ketamine infusion within 6 months;
  • Acute intoxication or active illegal substance abuse;

Key Trial Info

Start Date :

November 5 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 11 2020

Estimated Enrollment :

162 Patients enrolled

Trial Details

Trial ID

NCT04123652

Start Date

November 5 2017

End Date

November 11 2020

Last Update

December 4 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Allevio Pain Management Clinic

Toronto, Ontario, Canada, M3B 3S6